Navigation Links
Alba Therapeutics Announces Phase IIb Clinical Trial for Oral AT-1001 for the Treatment of Celiac Disease
Date:9/19/2007

g evaluated for the treatment of Type 1 Diabetes and Crohn's Disease. Results of the Company's first study in celiac patients are available online at:

http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2036.2007.03413 .x

About Alba

Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical company based in Baltimore, Maryland. Alba is dedicated to development and commercialization of disease-modifying therapeutics to treat autoimmune and inflammatory disease, drug delivery agents and mucosal vaccine adjuvants by exploiting its technology to regulate the assembly and disassembly of tight junctions in cell barriers throughout the body.

Contact: Bernard McDonald, PhD

Phone: 410-319-0780

E-mail: info@albatherapeutics.com

Web site: http://www.albatherapeutics.com


'/>"/>
SOURCE Alba Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Research and Markets ( ... "Investigation Report on China,s Ranibizumab Market, 2012-2019" report ... was approved by CFDA to treat wet age- related ... product of Novartis, is available in the Chinese market. ... drug for the treatment of wet AMD in ...
(Date:8/28/2015)... , Aug. 28, 2015 Perrigo Company ... on the Mylan N.V. ("Mylan") (NASDAQ: MYL ) ... Perrigo. "Our views of Mylan,s offer to ... be, based on our Board,s careful reflection of the ... on the limited choices that Mylan has allowed its ...
(Date:8/28/2015)... HERTFORDSHIRE, England and PITTSBURGH ... (NASDAQ: MYL ) today announced that its ... Company plc (NYSE: PRGO ; TASE) and ... Perrigo,s shareholders at an extraordinary general meeting of ... of two-thirds of the votes cast at the extraordinary general ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9
... Inc. (Nasdaq: NLTX ), a biopharmaceutical company ... disease, today announced that Michael R. Bristow, M.D. Ph.D. ... of CD-NP, a dual natriuretic peptide receptor agonist in ... Dr. Bristow, a recognized leader in ...
... Oct. 7 Reportlinker.com announces that a new ... U.S. Venous Access Catheter Market ... This study covers U.S. markets for venous access ... venous catheters (CVCs), dialysis catheters, implantable ports, and ...
Cached Medicine Technology:Michael R. Bristow, M.D. Ph.D. Joins Nile Therapeutics Scientific Advisory Board 2Michael R. Bristow, M.D. Ph.D. Joins Nile Therapeutics Scientific Advisory Board 3Reportlinker Adds U.S. Venous Access Catheter Market 2Reportlinker Adds U.S. Venous Access Catheter Market 3Reportlinker Adds U.S. Venous Access Catheter Market 4
(Date:8/29/2015)... ... August 29, 2015 , ... The popular television program ... Jones, recently announced that it will be devoting an entire short segment to the ... of people around the globe on a daily basis, but recent advancements in medical ...
(Date:8/28/2015)... ... August 28, 2015 , ... Approximately 2,000 United Methodists ... celebrate children helping children, a thank you to the many creative and generous ... to the United Methodist initiative to end malaria deaths. , The Columbus Zoo ...
(Date:8/28/2015)... Falls Church, VA (PRWEB) , ... ... ... and Cybersecurity Risk Management for Medical Devices:, Understanding the FDA’s Position and ... – Rockville, MD, http://www.fdanews.com/cybersecuritymd , This workshop, chaired by internationally ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... 20 grams of high grade protein with zero fat, carbs, sugar, gluten, lactose ... been named a finalist for the 2015 SupplySide CPG Editor’s Choice Awards. , ...
(Date:8/28/2015)... ... 28, 2015 , ... The Nashville Business Journal recently announced ... business. Mr. Troy Mizell, Chairman of the Board at MyGenetx, is one ... Veterans Awards will recognize Nashville military veterans who, through their professional and personal ...
Breaking Medicine News(10 mins):Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 2Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 3Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 4Health News:FDAnews Announces — Software and Cybersecurity Risk Management for Medical Devices: Understanding the FDA’s Position and Best Practices for Compliance, Oct. 14-15 5Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3Health News:MyGenetx Board Member Receives Veterans Award 2
... illnesses such as diabetes and high blood pressure when ... to a RAND Corporation study issued today. , Even ... new health plan year, a significant number of seniors ... findings published in the September/October edition of the journal ...
... Angeles, Sept. 14, 2007 -- A new study by researchers ... may be good for you. , Researchers found that ... dealt with teen obesity, hypertension and healthy eating habits had ... particularly among men. , The study, published in the Sept. ...
... concern and disappointment about reports that the pending SCHIP ... are critical to access to care for Medicare beneficiaries ... College of Physicians (ACP). David C. Dale, MD, ... the 124,000 internal medicine physicians and medical student members ...
... advance over invasive tests , , FRIDAY, Sept. 21 (HealthDay ... blood could become the lens through which doctors monitor ... study suggests. , "It,s amazing that all these pregnant ... blood," said Dr. Jill L. Maron, the study,s lead ...
... (Nasdaq: ADLS ), has received approval from the ... common stock,to the NASDAQ Capital Market from the NASDAQ ... of the Market today. The Company continues to be,listed ... http://www.newscom.com/cgi-bin/prnh/20050428/CGTH039LOGO ) "Advanced Life Sciences currently meets ...
... will honor,Texas House Speaker Tom Craddick and his wife, ... event that sold out faster and well,exceeded the amount ... participants and sponsors still on its waiting list. ... lent their names to,this important event, proceeds from the ...
Cached Medicine News:Health News:Study finds drug spending caps cause some seniors to quit taking key medicines 2Health News:ER episode impacts viewers' health knowledge and behavior 2Health News:'Deep concern and disappointment' with exclusion of Medicare from SCHIP legislation 2Health News:'Deep concern and disappointment' with exclusion of Medicare from SCHIP legislation 3Health News:Mother's Blood Could Offer Insights Into Fetal Health 2Health News:Mother's Blood Could Offer Insights Into Fetal Health 3Health News:Advanced Life Sciences Joins NASDAQ Capital Market 2Health News:2007 Speaker's Golf Tournament Sets 5-Year Fundraising Record 2
... is a freestanding cryostat with a ... and a radial cutting microtome. It ... wide range of specimens and materials ... in high biohazard risk laboratories where ...
The HM 550 series is a uniquely progressive concept for use with frozen specimens of all types. User applications define module selection and make even serial sectioning enjoyable....
... TP1020 product family are semi-enclosed tissue processors. ... of approved technology with modern and functionally ... safety for tissues at all stages of ... on proven precision mechanics in conjunction with ...
The HMP300 Histo Pro delivers all the features and benefits that conventional tissue processing have to offer....
Medicine Products: